Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia Cells
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aberrant histone deacetylase (HDAC) activity is frequent in human leukemias. However, while classical, NAD(+)-independent HDACs are an established therapeutic target, the relevance of NAD(+)-dependent HDACs (sirtuins) in leukemia treatment remains unclear. Here, we assessed the antileukemic activity of sirtuin inhibitors and of the NAD(+)-lowering drug FK866, alone and in combination with traditional HDAC inhibitors. Primary leukemia cells, leukemia cell lines, healthy leukocytes and hematopoietic progenitors were treated with sirtuin inhibitors (sirtinol, cambinol, EX527) and with FK866, with or without addition of the HDAC inhibitors valproic acid, sodium butyrate, and vorinostat. Cell death was quantified by propidium iodide cell staining and subsequent flow-cytometry. Apoptosis induction was monitored by cell staining with FITC-Annexin-V/propidium iodide or with TMRE followed by flow-cytometric analysis, and by measuring caspase3/7 activity. Intracellular Bax was detected by flow-cytometry and western blotting. Cellular NAD(+) levels were measured by enzymatic cycling assays. Bax was overexpressed by retroviral transduction. Bax and SIRT1 were silenced by RNA-interference. Sirtuin inhibitors and FK866 synergistically enhanced HDAC inhibitor activity in leukemia cells, but not in healthy leukocytes and hematopoietic progenitors. In leukemia cells, HDAC inhibitors were found to induce upregulation of Bax, a pro-apoptotic Bcl2 family-member whose translocation to mitochondria is normally prevented by SIRT1. As a result, leukemia cells become sensitized to sirtuin inhibitor-induced apoptosis. In conclusion, NAD(+)-independent HDACs and sirtuins cooperate in leukemia cells to avoid apoptosis. Combining sirtuin with HDAC inhibitors results in synergistic antileukemic activity that could be therapeutically exploited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 2×
“with a sirtuin inhibitor resulted in a synergistic enhancement of their cytotoxic activity, as shown by calculation of both cooperative index (CI) and combination index according to Chou and Talalay statistics (CI) [27,28].”
BackgroundMethodDanial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase
Cohen, H. Y., Miller, C., Bitterman, K. J., Wall, N. R., Hekking, B., Kessler, B., Howitz, K. T., Gorospe, M., de Cabo, R., & Sinclair, D. A. (2004) · Science · doi:10.1126/science.1099196 · Cited by 1,924
Van Gool, F., Gallí, M., Gueydan, C., Kruys, V., Prevot, P.-P., Bedalov, A., Mostoslavsky, R., Alt, F. W., De Smedt, T., & Leo, O. (2009) · Nature Medicine · doi:10.1038/nm.1906 · Cited by 285 · cited 3×
“The same applies to the Nampt inhibitor FK866 [20,21,22, 23,24,25].”
Backgroundvon Heideman, A., Berglund, Å., Larsson, R., & Nygren, P. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1125-3 · Cited by 201 · cited 2×
“Therefore, since Nampt inhibitors for clinical uses are already available and have shown to be well tolerated [36,37], these could in principle replace sirtuin inhibitors in combination protocols with HDAC inhibitors.”
BackgroundThe NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies
Nahimana, A., Attinger, A., Aubry, D., Greaney, P., Ireson, C., Thougaard, A. V., Tjørnelund, J., Dawson, K. M., Dupuis, M., & Duchosal, M. A. (2009) · Blood · doi:10.1182/blood-2008-08-173369 · Cited by 190 · cited 1×
“Studies show that FK866 has antileukemic activity in vitro and in leukemia and lymphoma animal models [38,39].”
Background
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Indole: A privileged scaffold for the design of anti-cancer agents
Wan, Y., Li, Y., Yan, C., Yan, M., & Tang, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111691 · Cited by 516
Seven sirtuins for seven deadly diseases ofaging
Morris, B. J. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.10.525 · Cited by 377
Grozio, A., Sociali, G., Sturla, L., Caffa, I., Soncini, D., Salis, A., Raffaelli, N., De Flora, A., Nencioni, A., & Bruzzone, S. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.470435 · Cited by 158
“LowMicromolar Concentrations of Extracellular NAD Rescue FK866-incubated Cells fromDeath—The addition of extracellularNAD or of theNAD precursorNMNorNRprevents FK866-induced cell death (23, 27, 28).”
BackgroundSelf-citationRecent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy
Galli, U., Colombo, G., Travelli, C., Tron, G. C., Genazzani, A. A., & Grolla, A. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00656 · Cited by 162
Metadata
- Authors
- Cea, M., Soncini, D., Fruscione, F., Raffaghello, L., Garuti, A., Emionite, L., Moran, E., Magnone, M., Zoppoli, G., Reverberi, D., Caffa, I., Salis, A., Cagnetta, A., Bergamaschi, M., Casciaro, S., Pierri, I., Damonte, G., Ansaldi, F., Gobbi, M., Pistoia, V., Ballestrero, A., Patrone, F., Bruzzone, S., & Nencioni, A.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-07-27
- Volume
- 6
- Issue
- 7
- Pages
- e22739
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2007415161
- Cited by
- 81
- References
- 6
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia Cells. https://app.cochat.ai/papers/10.1371/journal.pone.0022739
- The paper
- Cea, M., Soncini, D., Fruscione, F., Raffaghello, L., Garuti, A., Emionite, L., Moran, E., Magnone, M., Zoppoli, G., Reverberi, D., Caffa, I., Salis, A., Cagnetta, A., Bergamaschi, M., Casciaro, S., Pierri, I., Damonte, G., Ansaldi, F., Gobbi, M., . . . Nencioni, A. (2011). Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia Cells. PLoS ONE. https://doi.org/10.1371/journal.pone.0022739
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.